Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12480905 | 0.90 | ACACB (0.44) | KMT2AMEN1ACACBKDM4EALDH1A1 | |
| SCHEMBL19289085 | 0.90 | ACACB (0.44) | KMT2AMEN1ACACBKDM4EALDH1A1 | |
| SCHEMBL12542444 | 0.89 | ACACB (0.44) | KMT2AMEN1ACACBKDM4EALDH1A1 | |
| SCHEMBL12481197 | 0.89 | ACACB (0.44) | KMT2AMEN1ACACBKDM4EALDH1A1 | |
| SCHEMBL12481709 | 0.88 | ACACB (0.43) | KMT2AMEN1ACACBKDM4EALDH1A1 | |
| SCHEMBL12695171 | 0.88 | ACACB (0.43) | KMT2AMEN1ACACBKDM4EALDH1A1 | |
| SCHEMBL12695123 | 0.88 | ACACB (0.43) | KMT2AMEN1ACACBKDM4EALDH1A1 | |
| SCHEMBL12481866 | 0.88 | ACACB (0.43) | IDO1KMT2AMEN1ACACBKDM4E | |
| SCHEMBL12480939 | 0.87 | ACACB (0.42) | KMT2AMEN1ACACBKDM4EALDH1A1 | |
| SCHEMBL12480972 | 0.86 | ACACB (0.42) | IDO1KMT2AMEN1ACACBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-20 | — | — | US | disclosed |
| EP-2675812-B1 | CHROMAN - SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245136-A1 | CHROMAN-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, KCNJ1, KCNC1 | IDO1 3309/4885KMT2A 2130/4885MEN1 3240/4885 |
| US-10385070-B2 | Chroman-spirocyclic piperidine amides as modulators of ion channels | KCNJ2, KCNJ1, KCNC1 | IDO1 3309/4885KMT2A 2130/4885MEN1 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.